CLDF Title
Home | Contact Us | Bookmark
NASH HCC
Centers of Educational Expertise  
Live CME Events Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
 
Back  
 
Reuters Health Information: Worse COVID-19 outcomes with liver injury at presentation

Worse COVID-19 outcomes with liver injury at presentation

Last Updated: 2020-05-14

By Will Boggs MD

NEW YORK (Reuters Health) - Gastrointestinal and hepatic manifestations of COVID-19 are common, but only liver injury at presentation is associated with an increased risk of death or ICU admission, according to a new study from New York.

"Don't ignore GI manifestations; they may be the only symptoms," Dr. Reem Sharaiha from Weill Cornell Medicine, New York-Presbyterian Hospital, New York told Reuters Health by email.

Several recent reports have shown a high prevalence of gastrointestinal and hepatic manifestations in patients with COVID-19, especially in Western populations.

Dr. Sharaiha and colleagues of Weill Cornell Medicine, New York-Presbyterian Hospital, examined outcomes in 1,059 adult patients (mean age, 61 years) diagnosed with COVID-19.

At presentation, 22% of these patients had diarrhea, 7% had abdominal pain, 16% had nausea, 9% had vomiting and 62% had biochemical evidence of liver injury (i.e., at least one of their liver enzymes was elevated).

Overall, a third of the patients had at least one gastrointestinal manifestation, the authors report in Gastroenterology.

Female patients and patients with chronic liver disease were significantly more likely to present with gastrointestinal symptoms, and older age was associated with a slightly but significantly higher rate of liver-test abnormalities at presentation.

Admission rates were significantly higher among patients with gastrointestinal manifestations (78% vs. 70%) and among those with liver injury (87% vs. 76%, respectively).

Independent predictors of the composite outcome of death or ICU admission included liver injury at presentation (odds ratio, 2.53), older age (OR, 1.03), comorbidities (OR, 1.19), tachypnea (OR, 1.73) and severe hypoxia (OR, 1.47). Overall, gastrointestinal manifestations were not significantly associated with this outcome.

"Some GI manifestations, namely diarrhea, led to better outcomes," Dr. Sharaiha said. "This may mean that there are different strains or there is some reason people get different manifestations and different severities of disease."

"(It's) important to keep publishing on this topic, more so on clinical experience," he said.

"These results provide clarification of the diagnosis of patients with COVID-19 and can be considered in risk stratification," the authors conclude.

Dr. Sherief Musa of Cairo University, who recently reviewed the characteristics of hepatic and gastrointestinal involvement in COVID-19, told Reuters Health by email, "These findings should alert primary-care physicians or gastroenterologists to raise their index of suspicion during the current pandemic when patients present with digestive symptoms, rather than waiting for respiratory symptoms to emerge. This may help with earlier identification of COVID-19 with earlier treatment and isolation."

"Also, liver abnormalities should be taken seriously and considered in risk stratification of patients in addition to other comorbidities," said Dr. Musa, who was not involved in the study.

SOURCE: https://bit.ly/2WVFuUP Gastroenterology, online May 7, 2020.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2020 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.